Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials
- 15 June 1996
- Vol. 77 (12) , 2503-2513
- https://doi.org/10.1002/(sici)1097-0142(19960615)77:12<2503::aid-cncr13>3.0.co;2-w
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Cancer statistics, 1995CA: A Cancer Journal for Clinicians, 1995
- A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Current status of endocrine treatment of carcinoma of the breastSeminars in Surgical Oncology, 1990
- Oral medroxyprogesterone acetate in the treatment of metastatic breast cancerBreast Cancer Research and Treatment, 1985
- Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancerAmerican Journal of Clinical Oncology, 1982
- Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifenCancer, 1982
- Quantitative estrogen receptor analyses: The response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free intervalCancer, 1980
- Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancerCancer, 1980
- Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapyCancer, 1980
- Progestin therapy in advanced breast cancer: Megestrol acetate—an evaluation of 160 treated casesCancer, 1980